This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
BMYPositive Net Change PFEPositive Net Change CORTPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
by Zacks Equity Research
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
BIIBNegative Net Change BMRNNegative Net Change AGENPositive Net Change SAGEPositive Net Change
biotechnology biotechs
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
REGNPositive Net Change AMGNPositive Net Change NTLAPositive Net Change KRYSPositive Net Change
biotechs
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.
AMGNPositive Net Change ADVMPositive Net Change KRYSPositive Net Change DNAPositive Net Change
biotechs
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pe-ratio pharmaceuticals
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs earnings-preview medical messenger-rna pharmaceuticals vaccines
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
ANIPPositive Net Change VKTXPositive Net Change RAPTPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Alkermes (ALKS) reports mixed second-quarter 2024 results. Earnings and revenues decline year over year.
ALKSNegative Net Change ANIPPositive Net Change AXSMPositive Net Change RAPTPositive Net Change
biotechs earnings
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
by Ekta Bagri
Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.
BIIBNegative Net Change BMRNNegative Net Change AGENPositive Net Change SAGEPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
by Zacks Equity Research
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
SNYNegative Net Change AZNNegative Net Change MRKNegative Net Change AMGNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
GSKPositive Net Change JNJPositive Net Change HLNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
by Zacks Equity Research
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
NVSPositive Net Change AMGNPositive Net Change INCYPositive Net Change ADVMPositive Net Change
biotechs
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
by Zacks Equity Research
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
AMGNPositive Net Change AGENPositive Net Change ADVMPositive Net Change GPCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.
REGNPositive Net Change SNYNegative Net Change AMGNPositive Net Change SNDXNegative Net Change
biotechs medical pharmaceuticals
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
by Ekta Bagri
Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.
BMYPositive Net Change PFEPositive Net Change TSVTPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
SNYNegative Net Change AZNNegative Net Change BMYPositive Net Change ABBVPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.
GERNPositive Net Change AMGNPositive Net Change AGENPositive Net Change ADVMPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.
AMGNPositive Net Change VRTXPositive Net Change ADVMPositive Net Change CRSPPositive Net Change
biotechs
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
SNYNegative Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical pharmaceuticals vaccines
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
AMGNPositive Net Change ADMAPositive Net Change ADVMPositive Net Change CRSPPositive Net Change
biotechs
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
by Zacks Equity Research
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
GSKPositive Net Change JNJPositive Net Change RAPTPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
AZNNegative Net Change BMYPositive Net Change CORTPositive Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings-preview medical pharmaceuticals
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
by Zacks Equity Research
The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.
AGENPositive Net Change ANIPPositive Net Change ADPTPositive Net Change RAPTPositive Net Change
biotechs